1,712 Hits in 8.1 sec

H E-based Computational Biomarker Enables Universal EGFR Screening for Lung Adenocarcinoma [article]

Gabriele Campanella, David Ho, Ida Häggström, Anton S Becker, Jason Chang, Chad Vanderbilt, Thomas J Fuchs
2022 arXiv   pre-print
EGFR positive lung adenocarcinomas have been shown to have high response rates to TKI therapy, underlying the essential nature of molecular testing for lung cancers.  ...  Lung cancer is the leading cause of cancer death worldwide, with lung adenocarcinoma being the most prevalent form of lung cancer.  ...  We also investigated the predictive power of FDG PET images for determining the EGFR mutation status.  ... 
arXiv:2206.10573v1 fatcat:f4rynvrsjrbqtg4745ovbo6wk4

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis

Luo CL, Xu ZG, Chen H, Ji J, Wang YH, Hu W, Wang K, Zhang WW, Yuan CH, Wang FB
2018 Cancer Management and Research  
/0.892, and AUCZFAS1=0.780/0.744 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively).  ...  , Wuhan Children's Hospital, Huazhong University of Science and Technology, Wuhan, China *These authors contributed equally to this work Background: Tissue biopsy-based cancer diagnosis has limitations  ...  Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.  ... 
doaj:20ffd045cce74562a514b62a4c9a88e7 fatcat:eoqvswvj3jgb7clpmwxg2d3p3e

Diagnosis and Predictive Molecular Analysis of Non–Small-Cell Lung Cancer in the Africa-Middle East Region: Challenges and Strategies for Improvement

Tomas Slavik, Fatima Asselah, Najla Fakhruddin, Ahmed El Khodary, Fairouz Torjman, Elia Anis, Martin Quinn, Azzam Khankan, Keith M. Kerr
2014 Clinical Lung Cancer  
In nonsmall-cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification are already being utilised in the clinic.  ...  However, such predictive molecular testing is not currently a universally employed practice. This is particularly the case in developing countries where lung cancer is increasingly prevalent.  ...  For adenocarcinoma, biomarkers include mutations in KRAS and EGFR and the presence of an ALK rearrangement ( Figure 1 ) [3] [4] [5] 20] .  ... 
doi:10.1016/j.cllc.2014.06.005 pmid:25043210 fatcat:sl64ghjklbfe3lcibvfi4lwara

Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice

Robert Pirker, Martin Filipits
2016 Cancer Metastasis Review  
Personalized treatment of patients with advanced non-small-cell lung cancer based on clinical and molecular tumor features has entered clinical routine practice.  ...  The 2015 pathological classification of lung cancer mandates immunohistochemical and molecular analysis.  ...  Acknowledgments Open access funding provided by Medical University of Vienna.  ... 
doi:10.1007/s10555-016-9612-6 pmid:26970967 pmcid:PMC4821865 fatcat:kpyx3h7srracvmmi2jscpmcyju

Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment

Lai J, Du B, Wang Y, Wu R, Yu Z
2018 OncoTargets and Therapy  
Circulating tumor DNA (ctDNA) has been recognized as a sensitive and specific biomarker for the detection of early- and late-stage lung cancer, and next-generation sequencing (NGS) of ctDNA has been accepted  ...  ctDNA is effective in detecting gene mutations in lung cancer patients, and may be used as a liquid biopsy for lung cancer, which facilitates the development of precision treatment regimens for lung cancer  ...  lung cancer, while X-ray and computed tomography scan show great values in the screening of the malignancy. 15 In the current-omics era, the multi-omics platforms have identified increasing numbers of  ... 
doaj:67056692a57d4e7eaf93e568378ca84c fatcat:hqttrleiijaxrmfkmi3fhitzmq

The Role of Circulating Biomarkers in Lung Cancer

Sayuri Herath, Habib Sadeghi Rad, Payar Radfar, Rahul Ladwa, Majid Warkiani, Ken O'Byrne, Arutha Kulasinghe
2022 Frontiers in Oncology  
This review explores the clinical use of circulating tumour biomarkers found in liquid biopsy for screening, early diagnosis and prognostication of lung cancer patients.  ...  Lung cancer is the leading cause of cancer morbidity and mortality worldwide and early diagnosis is crucial for the management and treatment of this disease.  ...  Genomic Analyses Based on Pulmonary Adenocarcinoma in Situ Reveal Early Lung Cancer Signature.  ... 
doi:10.3389/fonc.2021.801269 pmid:35127511 pmcid:PMC8813755 fatcat:hsil5ci44ngi3eo4vy34snoj7m

Serum biomarker panels for diagnosis of gastric cancer

Tong WH, Ye F, He L, Cui LF, Cui M, Hu Y, Li W, Jiang J, Zhang DY, Suo J
2016 OncoTargets and Therapy  
, Jilin, People's Republic of China Purpose: Currently, serum biomarkers that are sufficiently sensitive and specific for early detection and risk classification of gastric adenocarcinomas are not known  ...  After selecting five proteins as candidate biomarkers, multivariate classification analyses were used to identify algorithms for diagnostic biomarker combinations.  ...  Keywords: gastric adenocarcinoma, cancer diagnosis, cancer screening, Luminex Introduction Gastric adenocarcinoma accounts for 40% of all new gastric cancer cases worldwide.  ... 
doaj:f9b907e762124a87871772e42685d302 fatcat:55nsjriluzefncolxh65redilq

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

Iñigo Ayestaran, Ana Galhoz, Elmar Spiegel, Ben Sidders, Jonathan R. Dry, Frank Dondelinger, Andreas Bender, Ultan McDermott, Francesco Iorio, Michael P. Menden
2020 Patterns  
We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors.  ...  High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored  ...  T790M mutant in lung adenocarcinoma.  ... 
doi:10.1016/j.patter.2020.100065 pmid:33205120 pmcid:PMC7660407 fatcat:visj4u3bmrbc5i3k73nt5k6bpq

Laser-emission imaging of nuclear biomarkers for high-contrast cancer screening and immunodiagnosis

Yu-Cheng Chen, Xiaotian Tan, Qihan Sun, Qiushu Chen, Wenjie Wang, Xudong Fan
2017 Nature Biomedical Engineering  
Different lasing thresholds of nuclei in cancer and normal tissues enabled the identification and multiplexed detection of nuclear proteomic biomarkers, with a high sensitivity for early-stage cancer diagnosis  ...  Laser-emission-based cancer screening and immunodiagnosis might find use in precision medicine and facilitate research in cell biology.  ...  We also thank the support of the Molecular Imaging Analysis Lab at the University of Michigan for cryostats and confocal microscopy. We would also like to thank Dr.  ... 
doi:10.1038/s41551-017-0128-3 pmid:29204310 pmcid:PMC5711465 fatcat:pq2rfovx7fhfretb22ka2otfhq

Discovering novel long non-coding RNA predictors of anticancer drug sensitivity beyond protein-coding genes [article]

Aritro Nath, Eunice Y.T. Lau, Adam M Lee, Paul Geeleher, William C.S. Cho, R. Stephanie Huang
2019 bioRxiv   pre-print
Large-scale cancer cell line screens have identified thousands of protein-coding genes (PCGs) as biomarkers of anticancer drug response.  ...  However, adjusting for effects of cis-PCGs revealed significant lncRNAs that augment drug response predictions for most drugs, including those with well-established clinical biomarkers.  ...  RNAseq (RSEM) expression levels of EGFR-AS1 and MIR205HG, and EGFR point mutation, copy number variation data, and survival data for 877 lung adenocarcinoma (LUAD) samples were retrieved using UCSC Xena  ... 
doi:10.1101/666156 fatcat:rjixcyr5trbkxgxcpyixe4jsaa

Liquid biopsy for lung cancers: an update on recent developments

Alberto E. Revelo, Alvaro Martin, Ricardo Velasquez, Prarthna Chandar Kulandaisamy, Jean Bustamante, Sevak Keshishyan, Gregory Otterson
2019 Annals of Translational Medicine  
Liquid biopsy in lung cancer is evolving as an important added tool for screening, early detection, monitoring, and even prognostication of lung cancer.  ...  Several biomarkers, from which important tumor genomic information is obtained, are currently the subject of ongoing investigation.  ...  The identification of these molecular alterations b y N G S i n s t e a d o f t h e l i m i t e d n a r r o w t a r g e t e d mutations identify by PCR based methods, could potentially be beneficial for  ... 
doi:10.21037/atm.2019.03.28 pmid:31516895 pmcid:PMC6712255 fatcat:4r7lw2twfje7fp52f3wsal5ngm

Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing

A. Narayan, N. J. Carriero, S. N. Gettinger, J. Kluytenaar, K. R. Kozak, T. I. Yock, N. E. Muscato, P. Ugarelli, R. H. Decker, A. A. Patel
2012 Cancer Research  
Detection of cell-free tumor DNA in the blood has offered promise as a cancer biomarker, but practical clinical implementations have been impeded by the lack of a sensitive and accurate method for quantitation  ...  As proof-of-principle, we showed the successful use of this method to follow treatment-associated changes in circulating tumor DNA levels in patients with non-small cell lung cancer.  ...  Harrington, H. Schilke, T. Chapman, E. Washington, and N. Lacks for assistance with phlebotomy; and P. Glazer and D. Brash for valuable comments on the manuscript.  ... 
doi:10.1158/0008-5472.can-11-4037 pmid:22581825 pmcid:PMC3426449 fatcat:n34bxqg7m5c6vhwrcl5xpi2ivu

4th Australian Lung Cancer Conference (ALCC), Adelaide, Australia, August 23-25, 2012

2012 Journal of Thoracic Oncology  
Aims: The emergence of new targeted therapies and clinical trials in lung adenocarcinoma suggest that routine molecular biomarker testing is warranted to detected subtypes of adenocarcinoma which will  ...  Results: So far 22 patients received a definite tissue diagnosis of lung adenocarcinoma, 8/22 with Stage III and 10/22 with Stage IV disease. 4/22 (19%) are positive for an EGFR mutation, with activating  ...  Taken together these data provide evidence that miR-625-3p has the potential to serve as a novel blood-based biomarker for MPM.  ... 
doi:10.1097/jto.0b013e318268ff90 fatcat:or2r7egwenbbth72q3hqkuvgjy


2015 Journal of Thoracic Oncology  
Estimates of tumor content from H&E stained sections vary between pathologists and there is no true standard.  ...  Most EGFR exon 20 insertion mutated lung adenocarcinomas -in lieu of innovative clinical trials -should be treated with evidence-based approaches for "oncogene negative" lung adenocarcinomas.  ...  Abstracts Journal of Thoracic Oncology • Volume 10, The clinical benefits of biomarker-driven targeted cancer therapy are clear in many tumor types, particularly in lung adenocarcinoma.  ... 
doi:10.1016/s1556-0864(16)30009-0 fatcat:dp7nw6kfnnekjimnadoi5bexpa


2012 Journal of Thoracic Oncology  
chest physicians, thoracic surgeons, and radiation oncologists are principally dealing with patients with primary lung carcinoma of usual histologies in their daily practice. they are mostly adenocarcinoma  ...  E. Del signore 1 , F.  ...  We did not find (log-rank test) any relationship between both gender (p=0.53) and underlying malignancy associated with MPE (p=0.89, 0.48, and 0.36 for secondary cancer, lung cancer, and mesothelioma,  ... 
doi:10.1097/jto.0b013e318253d2ff fatcat:gk4cuwksgnct3camgbii5vfqaq
« Previous Showing results 1 — 15 out of 1,712 results